GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Icosavax Inc (NAS:ICVX) » Definitions » Cyclically Adjusted PS Ratio

Icosavax (Icosavax) Cyclically Adjusted PS Ratio : (As of May. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Icosavax Cyclically Adjusted PS Ratio?

Icosavax does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


Icosavax Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Icosavax's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Icosavax Cyclically Adjusted PS Ratio Chart

Icosavax Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PS Ratio
- - - -

Icosavax Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Icosavax's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Icosavax's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Icosavax's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Icosavax's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Icosavax's Cyclically Adjusted PS Ratio falls into.



Icosavax Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Icosavax does not have a history long enough to calculate Cyclically Adjusted Revenue per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PS Ratio for this company.


Icosavax  (NAS:ICVX) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Icosavax Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Icosavax's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Icosavax (Icosavax) Business Description

Industry
Traded in Other Exchanges
N/A
Address
1930 Boren Avenue, Suite 1000, Seattle, WA, USA, 98101
Icosavax Inc is a biopharmaceutical company. It is committed towards developing safe and effective vaccines against infectious diseases against infectious diseases, with an initial focus on life-threatening respiratory diseases.
Executives
Adam K. Simpson director, officer: Chief Executive Officer C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Niranjan Kanesa-thasan officer: Chief Medical Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Cassia Cearley officer: Chief Business Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Thomas Joseph Russo officer: Chief Financial Officer C/O ASSEMBLY BIOSCIENCES, INC., 11711 N MERIDIAN ST, SUITE 310, CARMEL IN 46032
Douglas Holtzman officer: Chief Scientific Officer 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Amin Khan officer: EVP, Head of Research & Dev. C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC, 200 BOSTON AVENUE, SUITE 3100, MEDFORD MA 02155
Ra Capital Nexus Fund, L.p. director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Elizabeth Bekiroglu officer: See Remarks 1616 EASTLAKE AVENUE E, SUITE 208, SEATTLE WA 98102-3793
Charles E Richardson officer: See Remarks 1616 EASTLAKE AVENUE E., SUITE 208, SEATTLE WA 98102
Jim Wassil director C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
John W. Shiver director C/O ICOSAVAX, INC., 1616 EASTLAKE AVENUE E. SUITE 208, SEATTLE WA 98102
Anofi 10 percent owner 46 AVENUE DE LA GRANDE ARMEE, PARIS I0 75017
Nanodimension Iii, L.p. 10 percent owner GOVERNORS SQUARE UNIT 3-213, 23 LIME TREE BAY AVE, P.O. BOX 526, WEST BAY, GRAND CAYMAN E9 KY1-1302
Adams Street Partners Llc 10 percent owner ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807